Mangoceuticals Inc (NASDAQ: MGRX) is a telehealth-enabled pharmaceutical products company that sells prescription medications to consumers through an online platform. Revenue is generated transactionally when patients purchase pharmaceutical products prescribed via contracted telemedicine providers, with prescriptions fulfilled through Epiq Scripts, the company's designated pharmacy partner. The company is headquartered in Dallas, Texas, operating from approximately 2,467 square feet of leased office space at 17130 Dallas Parkway as of November 1, 2025. Mangoceuticals reported a net loss of $20,643,455 for the year ended December 31, 2025, compared to a net loss of $8,707,226 for the year ended December 31, 2024, with the wider loss driven by declining revenue and higher general and administrative expenses. Stock-based compensation was $10,794,245 for the year ended December 31, 2025. The company has a distribution agreement with ISFLST covering Asia Pacific and Latin American markets, running through July 8, 2027. Mangoceuticals qualifies as an emerging growth company and requires additional capital to sustain operations.

Revenue model

Transactional revenue from consumer purchases of prescription pharmaceutical products through the Mangoceuticals online platform, fulfilled via pharmacy partner Epiq Scripts after physician review by contracted telemedicine providers.

Products and services

Prescription pharmaceutical products sold direct-to-consumer via a telehealth platform. Telemedicine provider physicians evaluate patient eligibility and issue prescriptions electronically to Epiq Scripts for fulfillment.

Customers and end markets

Individual consumers seeking prescription pharmaceutical products through a direct-to-consumer telehealth model. End market is retail patients, with physician eligibility screening required prior to each prescription.

Value-chain role

Platform operator sitting between contracted telemedicine providers, who handle physician consults and prescriptions, and Epiq Scripts, the designated pharmacy partner that fulfills orders. Holds a non-exclusive distribution agreement with ISFLST for product sales in Asia Pacific and Latin America (excluding Mexico) through July 8, 2027.

Geographic exposure

Primary operations in the United States, headquartered in Dallas, Texas. Distribution agreement with ISFLST covers Asia Pacific and Latin America (excluding Mexico) markets.

Source: SEC 10-K, filed 2026-04-01

Industry: Services-Misc Health & Allied Services, NEC Peers: CLS Holdings USA, Inc. MedAvail Holdings, Inc. NEW RITE AID, LLC Walgreens Boots Alliance, Inc.